Aspirin and Cancer Treatment: Systematic Reviews and Meta-analyses of Evidence: for and Against

Overview

Journal Br J Cancer

Specialty Oncology

Date 2023 Nov 29

PMID 38030748

Authors

Peter Elwood

Gareth Morgan

John Watkins

Majd Protty

Malcolm Mason

Richard Adams

Sunil Dolwani

Janet Pickering

Christine Delon

Marcus Longley

Affiliations

Soon will be listed here.

Abstract

Aspirin as a possible treatment of cancer has been of increasing interest for over 50 years, but the balance of the risks and benefits remains a point of contention. We summarise the valid published evidence 'for' and 'against' the use of aspirin as a cancer treatment and we present what we believe are relevant ethical implications. Reasons for aspirin include the benefits of aspirin taken by patients with cancer upon relevant biological cancer mechanisms. These explain the observed reductions in metastatic cancer and vascular complications in cancer patients. Meta-analyses of 118 observational studies of mortality in cancer patients give evidence consistent with reductions of about 20% in mortality associated with aspirin use. Reasons against aspirin use include increased risk of a gastrointestinal bleed though there appears to be no valid evidence that aspirin is responsible for fatal gastrointestinal bleeding. Few trials have been reported and there are inconsistencies in the results. In conclusion, given the relative safety and the favourable effects of aspirin, its use in cancer seems justified, and ethical implications of this imply that cancer patients should be informed of the present evidence and encouraged to raise the topic with their healthcare team.

Citing Articles

Aspirin-triggered DHA metabolites inhibit angiogenesis.

Vara-Messler M, Trevisi L, Zulato E, Ramaschi G, Rise P, Pinna C Front Pharmacol. 2025; 16:1524980.

PMID: 40070577 PMC: 11893558. DOI: 10.3389/fphar.2025.1524980.

Unveiling the pH-Responsive Mechanisms of the Carbon Dot-Proximicin-A Peptide Conjugate for Targeted Cancer Therapy Using Density Functional Theory.

Ahamed A, Samaranayake P, Silva V, Kooh M, Wickramage N, Rajapaksha I Molecules. 2025; 30(4).

PMID: 40005204 PMC: 11858495. DOI: 10.3390/molecules30040896.

Microbes, macrophages, and melanin: a unifying theory of disease as exemplified by cancer.

Berg S, Berg J Front Immunol. 2025; 15:1493978.

PMID: 39981299 PMC: 11840190. DOI: 10.3389/fimmu.2024.1493978.

Chemopreventive strategies for sporadic colorectal cancer: a narrative review.

Monson S, Chen P, Gangi A, Waters K, Billet S, Hendifar A Transl Gastroenterol Hepatol. 2025; 10:11.

PMID: 39944579 PMC: 11811562. DOI: 10.21037/tgh-24-97.

Risks of anti- therapy and long-term therapy with antisecretory drugs.

Kotelevets S World J Gastroenterol. 2025; 31(4):101933.

PMID: 39877710 PMC: 11718649. DOI: 10.3748/wjg.v31.i4.101933.

References

Downer M, Allard C, Preston M, Gaziano J, Stampfer M, Mucci L . Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health Study. Eur Urol. 2017; 72(5):821-827. DOI: 10.1016/j.eururo.2017.01.044. View

Denk D, Greten F . Inflammation: the incubator of the tumor microenvironment. Trends Cancer. 2022; 8(11):901-914. DOI: 10.1016/j.trecan.2022.07.002. View

Hansson L, Zanchetti A, Carruthers S, Dahlof B, Elmfeldt D, Julius S . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351(9118):1755-62. DOI: 10.1016/s0140-6736(98)04311-6. View

Li P, Ning Y, Li M, Cai P, Siddiqui A, Liu E . Aspirin Is Associated With Reduced Rates of Venous Thromboembolism in Older Patients With Cancer. J Cardiovasc Pharmacol Ther. 2020; 25(5):456-465. DOI: 10.1177/1074248420925021. View

Sokol D . Update on the UK law on consent. BMJ. 2015; 350:h1481. DOI: 10.1136/bmj.h1481. View

Elwood P, Morgan G, Galante J, Chia J, Dolwani S, Graziano J . Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk. PLoS One. 2016; 11(11):e0166166. PMC: 5113022. DOI: 10.1371/journal.pone.0166166. View

Zhang X, Du R, Luo N, Xiang R, Shen W . Aspirin mediates histone methylation that inhibits inflammation-related stemness gene expression to diminish cancer stemness via COX-independent manner. Stem Cell Res Ther. 2020; 11(1):370. PMC: 7450956. DOI: 10.1186/s13287-020-01884-4. View

Nounu A, Greenhough A, Heesom K, Richmond R, Zheng J, Weinstein S . A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2020; 30(3):564-575. PMC: 8086774. DOI: 10.1158/1055-9965.EPI-20-1176. View

Patrono C, Garcia Rodriguez L, Landolfi R, Baigent C . Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005; 353(22):2373-83. DOI: 10.1056/NEJMra052717. View

10.

Lichtenberger L, Vijayan K . Are Platelets the Primary Target of Aspirin's Remarkable Anticancer Activity?. Cancer Res. 2019; 79(15):3820-3823. PMC: 6679799. DOI: 10.1158/0008-5472.CAN-19-0762. View

11.

Elwood P, Morgan G, Delon C, Protty M, Galante J, Pickering J . Aspirin and cancer survival: a systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers. Ecancermedicalscience. 2021; 15:1258. PMC: 8426031. DOI: 10.3332/ecancer.2021.1258. View

12.

Lyman G, Khorana A, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M . American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007; 25(34):5490-505. DOI: 10.1200/JCO.2007.14.1283. View

13.

Guo Y, Liu Y, Zhang C, Su Z, Li W, Huang M . The epigenetic effects of aspirin: the modification of histone H3 lysine 27 acetylation in the prevention of colon carcinogenesis in azoxymethane- and dextran sulfate sodium-treated CF-1 mice. Carcinogenesis. 2016; 37(6):616-624. PMC: 5006120. DOI: 10.1093/carcin/bgw042. View

14.

Motta R, Cabezas-Camarero S, Torres-Mattos C, Riquelme A, Calle A, Figueroa A . Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives. J Clin Transl Res. 2021; 7(4):511-522. PMC: 8445628. View

15.

Sturgeon K, Deng L, Bluethmann S, Zhou S, Trifiletti D, Jiang C . A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019; 40(48):3889-3897. PMC: 6925383. DOI: 10.1093/eurheartj/ehz766. View

16.

Giorli G, Rouette J, Yin H, Lapi F, Simonetti M, Cricelli C . Prediagnostic use of low-dose aspirin and risk of incident metastasis and all-cause mortality among patients with colorectal cancer. Br J Clin Pharmacol. 2020; 86(11):2266-2273. PMC: 7576616. DOI: 10.1111/bcp.14329. View

17.

Henry W, Laszewski T, Tsang T, Beca F, Beck A, McAllister S . Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling. Cancer Res. 2016; 77(3):790-801. PMC: 5290090. DOI: 10.1158/0008-5472.CAN-16-2400. View

18.

Elwood P, Protty M, Morgan G, Pickering J, Delon C, Watkins J . Aspirin and cancer: biological mechanisms and clinical outcomes. Open Biol. 2022; 12(9):220124. PMC: 9470249. DOI: 10.1098/rsob.220124. View

19.

Gay L, Felding-Habermann B . Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011; 11(2):123-34. PMC: 6894505. DOI: 10.1038/nrc3004. View

20.

Chia W, Ali R, Toh H . Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol. 2012; 9(10):561-70. DOI: 10.1038/nrclinonc.2012.137. View